

**ASCO Direct[™] Highlights:
Therapeutic Immuno-Oncology Advances for the Practitioner**

via Zoom Video Conference
Thursday, October 8, 2020

Time	Title	Speaker, Institution
8:30 – 8:35 AM	Welcome Remarks	Jonathan D. Licht, MD University of Florida
IMMUNOTHERAPY PRINCIPLES		
8:35 – 9:05 AM	<i>Role of Microbiota in Immunotherapy Response and Toxicity</i>	Christian Jobin, PhD University of Florida
9:05 – 9:35 AM	<i>New Advances In Vaccines & Adoptive Cellular Therapies</i>	Duane Mitchell, MD, PhD University of Florida
9:35 – 9:50 AM	<i>Q & A</i>	
CLINICAL UPDATES & RECENT IMMUNO-ONCOLOGY APPROVALS		
9:50 – 10:05 AM	<i>Recent Approvals and Clinical Updates for Immuno-Oncology in Neuro & Pediatrics</i>	Elias Sayour, MD, PhD University of Florida
10:05 – 10:20 AM	<i>Recent Approvals and Clinical Updates for Car-T Cell Therapy</i>	Jack W. Hsu, MD University of Florida
10:20 – 10:50 AM	<i>Recent Approvals and Clinical Updates for Immuno-Oncology in Breast Cancer</i>	Leisha A. Emens, MD, PhD University of Pittsburgh Cancer Center
10:50 – 11:05 AM	<i>Q & A</i>	
11:05 – 11:20 AM	<i>Recent Approvals and Clinical Updates for Immuno-Oncology in Gynecologic Cancers</i>	Martina Murphy, MD University of Florida
11:20 – 11:35 AM	<i>Recent Approvals and Clinical Updates for Immuno-Oncology in Genitourinary Cancers</i>	Jonathan A. Chatzkel, MD University of Florida
11:35 – 11:55 AM	<i>Recent Approvals and Clinical Updates for Immuno-Oncology in Gastrointestinal Cancers</i>	Sherise Rogers, MD, MPH University of Florida

Sponsored by:



11:55 – 12:25 PM	<i>Recent Approvals and Clinical Updates for Immuno-Oncology in Lung and Head & Neck Cancers</i>	Devika Das, MD The University of Alabama at Birmingham
12:25 – 12:40 PM	<i>Q & A</i>	
12:40 – 1:00 PM	Lunch	
TOXICITY MANAGEMENT AND SPECIAL POPULATIONS		
1:00 – 1:30 PM	<i>Management of Acute and Chronic Immune Reactions</i>	Brian H. Ramnarain, MD University of Florida
1:30 – 2:00 PM	<i>Immuno-Oncology Management in Special Populations: Autoimmune Diseases; Poor Performance Status; Elderly and Diabetic Patients; Covid19 Positive Patients</i>	Panel Discussion moderated by: David DeRemer, PharmD, BCOP with: Brian H. Ramnarain, MD Zeina A. Al-Mansour, MD Dennie Jones, Jr, MD University of Florida
FUTURE DIRECTIONS		
2:00 – 2:30 PM	<i>Rational Approaches and Future Directions in Immuno-Oncology Therapies</i>	Samir N. Khleif, MD Georgetown University Cancer Center
2:30 – 2:45PM	<i>Q & A</i>	
2:45 – 2:50 PM	Closing Remarks	Jonathan D. Licht, MD University of Florida

Continuing Medical Education:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida AHEC Network and UF Health Cancer Center. The Florida AHEC Network is accredited by the Florida Medical Association to provide continuing medical education to physicians. The Florida AHEC Network designates this live activity for a maximum of 5.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Disclosures: Christian Jobin, PhD, is a consultant/speakers' bureau for Bristol-Myers Squibb, BiomX and Arrata Bio; and a stock shareholder for Evelo Biosciences. Leisha Emens, MD, PhD, is a consultant/speakers' bureau for AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Chugai, Genetech, Gritstone, Medimmune, MacroGenics, Novartis, Peregrine, Replimmune, Roche, and Syndax, Vaccinex; and a stock shareholder for Aduro IND. Dr. David DeRemer's spouse is a consultant/speakers' bureau for BMS, Pfizer and Amgen. Dr. Samir Khleif receives grant/research support from AstraZeneca, Bioline Therapeutics, Bristol-Myers Squibb, IO Biotechnologies, Merck, Syndax, Lycera, KAHR Medical; is a

Sponsored by:



ASCO DirectTM

Highlights



consultant/speakers' bureau for Agonox, Bayer, Autolus, Glazo-Smith Kline, Rheos Medicine; and is a stock shareholder for Advaxis, Northwest Bio, PDS Biotechnology, IO Biotechnology, KAHR Medical. Dr. Emens will be discussing clinical trial testing unapproved drugs. Dr. Devika Das will be discussing off-label use or investigational product. No other planners or presenters have any relevant financial disclosures.

Continuing Education

Suwannee River Area Health Education Center, Inc. is a Florida Board of Nursing and Pharmacy approved provider of continuing education. CE Broker Provider ID #50-1922. This program meets the requirements for up to 5.5 contact hours.



Sponsored by:

